Core Viewpoint - Hongyuan Pharmaceutical (301246.SZ) is currently experiencing a significant decline in stock price, closing at 20.82 yuan with a drop of 7.05%, indicating a state of being below the initial offering price [1]. Group 1: Stock Performance - On its first day of trading, Hongyuan Pharmaceutical reached a peak stock price of 45 yuan, but has since experienced a downward trend [2]. - The stock was listed on March 20, 2023, and has been in a state of decline since its initial high [1][2]. Group 2: Fundraising and Financials - The total amount raised from the initial public offering (IPO) was 236.286 million yuan, with a net amount of 219.584 million yuan after deducting issuance costs [2]. - The net fundraising amount exceeded the original plan by 154.511 million yuan, indicating strong investor interest [2]. - The company initially planned to raise 65.073 million yuan for various projects, including a research center and high-end formulation production [2]. Group 3: Issuance Costs - The total issuance costs for the IPO amounted to 16.701 million yuan, with underwriting and sponsorship fees accounting for 13.932 million yuan [3].
宏源药业跌7.05% 2023年上市即巅峰超募15亿